Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
about
Lamivudine for chronic hepatitis B in adultsAdvances in immunomodulating therapy of HBV infectionHigh rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.Immunology of hepatitis B virus and hepatitis C virus infectionSuppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production.Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatmentThe woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infectionMechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis BImmune therapy including dendritic cell based therapy in chronic hepatitis B virus infection.Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Intrahepatic T cells in hepatitis B: viral control versus liver cell injury.Profound suppression of hepatitis B virus replication with lamivudine.Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha.Lamivudine for hepatitis B in clinical practice.Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.Management of viral hepatitis B.In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovirUse of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection.Nucleoside analogues in the treatment of chronic hepatitis B.How can the cellular immune response control hepatitis B virus replication?Type 1/Type 2 immunity in infectious diseases.Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.Combination treatment in HBeAg-negative chronic hepatitis B.Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function.T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infectionCellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy.Chronic hepatitis B: current and future treatment options.Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy.Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load
P2860
Q24246121-257D2260-2A8C-4D14-B411-0624E944D566Q24810147-E8FF22F2-9130-4D80-A490-9BF1DEF4C534Q24814210-762B8BB0-AD3D-42FD-8344-04DBE0E24409Q28742762-E56E28F3-8FF1-4B57-B999-D8F749E76A6DQ29618957-5012AF3A-261A-494D-95DE-6EEA441AD739Q31906856-2C592F39-59F0-4445-B891-5ED7C7345158Q33211869-B052B4FA-DB89-445D-8329-4A2A4757C267Q33370720-DB3D0430-99B9-4EA6-9AEC-636B830729ECQ33549555-5AEB565D-CF63-46CC-9EE5-56AF8423B4CCQ33747793-DD7787F1-2DE7-4505-91CC-53F8E6DE4B9DQ33787525-31DF75E0-90FF-4D9F-9ACF-AD16006FC4DEQ33867509-5DAABD2D-27C7-47BD-85B3-FA23C16414CBQ33867720-D338BFFA-0AD9-4D37-8224-051E6BB16AF7Q33872988-93384D57-EB8D-424B-B829-570BD3FFF9F0Q33894481-FAC5A9D8-77C4-40F1-B3E9-CA265CE31C41Q33947154-4F92E3CF-E45F-4A49-8D80-2C9F73CD0F74Q33947160-A73B659C-F6C4-415B-AA4D-76C7FF250C45Q33947173-3643277C-D539-4A49-B019-909D2300AAB0Q33948393-8BFC916F-7AC3-43F9-A8FA-B8AEB2A3D4B1Q33950164-EF6A6943-95A7-4058-9EF6-E1A3A11FF145Q33959006-C13E8F80-F80B-4A35-A428-5C12128666BCQ33978910-BBD94C25-AD37-4E2C-B415-E7889BAD4959Q33988059-9D52271B-7488-47E9-8BED-9B0B712B521EQ33988066-B03DF58F-7E05-4565-B944-26D43FE16535Q34022674-03C34803-4A0E-49FE-B7DD-8B7838933544Q34105379-38C6511D-A4EA-4385-AA31-EB6FE73DF54EQ34330228-C11653B0-85E0-4390-93E1-2E70FFD1271AQ34344082-AEFC556D-9476-4D62-A3A2-AFF26C084B0FQ34362568-DBE4629F-6B92-4CB1-BF3F-70CD3881AA09Q34365631-0EE3B687-91C0-41CC-8275-6464E48E5828Q34391476-75DD0839-22F7-41F2-8BB9-16EA11204A9EQ34409291-E20552BB-DAF5-4050-B3EB-44F815C8ACCAQ34430261-DF601A07-F892-4CEE-83EF-E846605CD69BQ34550760-F3966BC8-98DF-41D4-B571-DA42441B1550Q34619603-78BA57C9-474D-4AAA-A544-A646C8F5E7F7Q34626075-94A616C6-639B-4B96-A37F-BD83792E32A9Q34687438-4A4B1BD0-3929-4C19-91F5-FEA05BC06B29Q34742036-CFC9A846-B2FC-4952-9EEC-9348D0515411Q34975716-941BBBB5-5D43-47CD-B90D-F0B7BB8E311CQ35574310-E5045726-8BD0-4EB7-B86C-BD6DB7EA483F
P2860
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
@en
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
@nl
type
label
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
@en
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
@nl
prefLabel
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
@en
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
@nl
P2093
P2860
P356
P1476
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
@en
P2093
A Bertoletti
F Fiaccadori
P Scognamiglio
R Panebianco
P2860
P304
P356
10.1172/JCI3731
P407
P577
1998-09-01T00:00:00Z